Braveheart Bio, Inc. (BRVE) stock
BRVENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026
$20.39+1.12 (+5.81%)
Close on Nov 20, 2026Market cap $1.84BP/E –Yield –
Braveheart Bio gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
No gross profit figures for Braveheart Bio
Braveheart Bio has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?